Crossmark

The alpha-1A adrenergic receptor agonist A61603 reduces cardiac polyunsaturated fatty acid and endocannabinoid metabolites associated with inflammation in vivo

Crossref DOI link: https://doi.org/10.1007/s11306-016-1097-3

Published Online: 2016-09-15

Published Print: 2016-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Willis, Monte S.

Ilaiwy, Amro

Montgomery, Megan D.

Simpson, Paul C.

Jensen, Brian C.
Funding

Funding for this research was provided by:

National Institutes of Health (R01HL10412)

Jefferson-Pilot Corporation

Leducq Foundation Transatlantic Networks of Excellence

National Heart, Lung, and Blood Institute (R01HL31113)
License Information

Text and Data Mining valid from 2016-09-15

Version of Record valid from 2016-09-15
More Information

Article History

Received: 11 May 2016

Accepted: 11 August 2016

First Online: 15 September 2016

Compliance with ethical standards

:

: The authors declare that they have no conflict of interest.

: All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.

Document is current

Any future updates will be listed below